Nicotinamide chemoprevention for keratinocyte carcinoma in solid organ transplant recipients: a multi-centre, pragmatic randomized trial
Overview
This clinical trial evaluates whether a specific type of vitamin helps to prevent skin cancer in transplant recipients.
A common long-term side effect of anti-rejection (immunosuppressant) medications is skin cancer. Previous research found that taking higher amounts of this vitamin helps to reduce skin cancer in the general population.
Our study will tell us whether the vitamin is useful and safe for reducing skin cancer in transplant patients.
Participant Commitment:
- The duration of this study for each participant will vary from 2 to 4 years depending on how long it takes to recruit everyone.
- The entire study is expected to take approx. 5 years to complete.
Eligibility
We invite people to participate if they have had a kidney, liver, heart, or lung transplant AND skin cancer.
People who qualify and wish to participate will need to:
- Take a pill twice a day
- Have regular follow-up skin exams and answer some questions every 4 months
